CombiGene AB (publ)

Stockholm Stock Exchange COMBI.ST

CombiGene AB (publ) Total Non-Current Liabilities for the year ending December 31, 2023

CombiGene AB (publ) Total Non-Current Liabilities is NA for the year ending December 31, 2023. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

CombiGene AB (publ) Total Non-Current Liabilities for the year ending December 31, 2019 was USD -0.11.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Stockholm Stock Exchange: COMBI.ST

CombiGene AB (publ)

CEO	Mr. Peter Ekolind
IPO Date	May 25, 2015
Location	Sweden
Headquarters	Agavagen 52A
Employees	10
Sector	Healthcare
Industries Biotechnology

Description

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.

Key trends

Past 5 years